0001209191-23-045766.txt : 20230815 0001209191-23-045766.hdr.sgml : 20230815 20230815080010 ACCESSION NUMBER: 0001209191-23-045766 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230814 FILED AS OF DATE: 20230815 DATE AS OF CHANGE: 20230815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chambers Michael Andrew CENTRAL INDEX KEY: 0001932527 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 231173239 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-14 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001932527 Chambers Michael Andrew 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 1 0 0 0 0 Common Stock 2023-08-14 4 P 0 5947 109.19 A 242964 I By Revocable Trust Common Stock 2023-08-14 4 P 0 4032 109.89 A 246996 I By Revocable Trust Common Stock 6431 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $109.67 to $110, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. /s/ Ryan Brown, as Attorney-in-Fact for Michael Chambers 2023-08-15